Latest & greatest articles for asthma

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on asthma or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on asthma and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for asthma

321. Are long-acting muscarinic antagonists (LAMAs) effective in adults with poorly controlled asthma?

Are long-acting muscarinic antagonists (LAMAs) effective in adults with poorly controlled asthma? Are long-acting muscarinic antagonists (LAMAs) effective in adults with poorly controlled asthma? - Evidently Cochrane Search and hit Go By March 24, 2016 // A blog for clinicians written by Lynda Ware, giving an overview of four recent Cochrane reviews assessing the effectiveness of LAMAs in asthma care. In the UK 5.4 million people are receiving treatment for asthma. This equates to 1:11 children (...) and 1:12 adults. In 2014 1216 people died from asthma, or, put another way, about 3 people every day. In addition, a patient was hospitalised every 8 minutes as a result of asthma. The cost to the NHS is around £1billion pounds per year. All this is happening despite our greatly improved understanding of the disease and of its treatment. Is there a role for LAMAs in asthma management? Long-acting muscarinic antagonists (LAMAs) are known to be effective in chronic obstructive pulmonary disease

2016 Evidently Cochrane

322. Safety of Fluticasone plus Salmeterol in Asthma - Reassuring Data, but No Final Answer. (Abstract)

Safety of Fluticasone plus Salmeterol in Asthma - Reassuring Data, but No Final Answer. 26946980 2016 05 25 2018 12 02 1533-4406 374 19 2016 May 12 The New England journal of medicine N. Engl. J. Med. Safety of Fluticasone plus Salmeterol in Asthma--Reassuring Data, but No Final Answer. 1887-8 10.1056/NEJMe1601040 Martinez Fernando D FD From the Arizona Respiratory Center, University of Arizona, Tucson. eng Editorial Comment 2016 03 06 United States N Engl J Med 0255562 0028-4793 0 (...) Bronchodilator Agents 0 Fluticasone-Salmeterol Drug Combination CUT2W21N7U Fluticasone AIM IM N Engl J Med. 2016 May 12;374(19):1822-30 26949137 Asthma drug therapy Bronchodilator Agents therapeutic use Female Fluticasone therapeutic use Fluticasone-Salmeterol Drug Combination therapeutic use Humans Male 2016 3 8 6 0 2016 3 8 6 0 2016 5 26 6 0 ppublish 26946980 10.1056/NEJMe1601040

2016 NEJM

323. Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone. Full Text available with Trip Pro

Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone. The safe and appropriate use of long-acting beta-agonists (LABAs) for the treatment of asthma has been widely debated. In two large clinical trials, investigators found a potential risk of serious asthma-related events associated with LABAs. This study was designed to evaluate the risk of administering the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate.In this multicenter (...) , randomized, double-blind trial, adolescent and adult patients (age, ≥12 years) with persistent asthma were assigned to receive either fluticasone with salmeterol or fluticasone alone for 26 weeks. All the patients had a history of a severe asthma exacerbation in the year before randomization but not during the previous month. Patients were excluded from the trial if they had a history of life-threatening or unstable asthma. The primary safety end point was the first serious asthma-related event (death

2016 NEJM Controlled trial quality: predicted high

324. Asthma in Children - Diagnosis and Management

during exacerbations is effective in long-term asthma control. Chest . 2000;117:440-446. 25 Garrett J, Williams S, Wong C, Holdaway D. Treatment of acute asthmatic exacerbations with an increased dose of inhaled steroid. Arch Dis Child . 1998;79:12-17. 26 Harrison T, Oborne J, Newton S, Tattersfield A. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet . 2004;363:271-275. 27 Oborne J, Mortimer K, Hubbard RB, Tattersfield AE, Harrison TW (...) micrograms/day with inhaled beclomethasone dipropionate 400 micrograms/day in mild and moderate asthma. Arch Dis Child . 1993;69:206-211. 32 Hoekx JC, Hedlin G, Pedersen W, Sorva R, Hollingworth K, Efthimiou J. Fluticasone propionate compared with budesonide: a double-blind trial in asthmatic children using powder devices at a dosage of 400 microg x day(-1). Eur Respir J . 1996;9:2263-2272. 33 Pedersen S, Garcia Garcia ML, Manjra A, Theron I, Engelstatter R. A comparative study of inhaled ciclesonide 160

2016 Clinical Practice Guidelines and Protocols in British Columbia

325. Asthma in Adults - Recognition, Diagnosis and Management

Asthma in Adults - Recognition, Diagnosis and Management Asthma in Adults - Recognition, Diagnosis and Management - Province of British Columbia theme_3_collection theme_3_frontend theme_3_collection theme_3_frontend Birth, Adoption, Death, Marriage & Divorce theme_1_collection theme_1_frontend theme_1_collection theme_1_frontend British Columbians & Our Governments theme_data_collection data_frontend theme_data_collection data_frontend Data theme_5_collection theme_5_frontend (...) theme_10_collection theme_10_frontend Sports, Recreation, Arts & Culture theme_8_collection theme_8_frontend theme_8_collection theme_8_frontend Taxes & Tax Credits theme_14_collection theme_14_frontend theme_14_collection theme_14_frontend Tourism & Immigration Search default_collection default_frontend Section Navigation Asthma in Adults - Recognition, Diagnosis and Management Effective Date: October 28, 2015 Recommendations and Topics Scope This guideline provides recommendations for the recognition, diagnosis

2016 Clinical Practice Guidelines and Protocols in British Columbia

326. Patterns, predictors and outcomes of asthma control and exacerbations during pregnancy: a prospective cohort study Full Text available with Trip Pro

Patterns, predictors and outcomes of asthma control and exacerbations during pregnancy: a prospective cohort study There exists a paucity of data for socially disadvantaged populations describing patterns and predictors of asthma control status and exacerbations during pregnancy, and their relationship to adverse perinatal outcomes. Asthmatic women (n=189) were followed prospectively during pregnancy, with visits at 12, 20, 28 and 36 weeks gestation. Data on loss of control, recurrent (...) uncontrolled asthma and moderate/severe exacerbations were collected at each visit and their relationship to perinatal outcomes examined following stratification for fetal sex. 50% of asthmatic women experienced a loss of control or moderate/severe exacerbation during pregnancy, with 22% of women experiencing a moderate/severe exacerbation. Factors associated with an increased risk of women experiencing recurrent uncontrolled asthma during pregnancy included smoking (relative risk 2.92, 95% CI 1.53-5.58

2016 ERJ open research

327. Effect of Prenatal Supplementation With Vitamin D on Asthma or Recurrent Wheezing in Offspring by Age 3 Years: The VDAART Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Prenatal Supplementation With Vitamin D on Asthma or Recurrent Wheezing in Offspring by Age 3 Years: The VDAART Randomized Clinical Trial. Asthma and wheezing begin early in life, and prenatal vitamin D deficiency has been variably associated with these disorders in offspring.To determine whether prenatal vitamin D (cholecalciferol) supplementation can prevent asthma or recurrent wheeze in early childhood.The Vitamin D Antenatal Asthma Reduction Trial was a randomized, double-blind (...) , placebo-controlled trial conducted in 3 centers across the United States. Enrollment began in October 2009 and completed follow-up in January 2015. Eight hundred eighty-one pregnant women between the ages of 18 and 39 years at high risk of having children with asthma were randomized at 10 to 18 weeks' gestation. Five participants were deemed ineligible shortly after randomization and were discontinued.Four hundred forty women were randomized to receive daily 4000 IU vitamin D plus a prenatal vitamin

2016 JAMA Controlled trial quality: predicted high

328. Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial. (Abstract)

Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial. Specific allergen immunotherapy is the only treatment modality that might change the natural course of allergic diseases in childhood. We sought to prospectively compare the long-term clinical and immunological effects of sublingual (SLIT) and subcutaneous (SCIT) immunotherapy compared with pharmacotherapy alone.In this single (...) -center, prospective randomized controlled trial, 48 children with mild persistent asthma with/without rhinitis, monosensitized to house dust mites (HDMs) were followed for 3 years. At baseline and years 1 and 3 of follow-up, patients were evaluated and compared for total rhinitis (TRSS) and asthma (TASS) symptom scores, total symptom scores (TSS), total medication scores (TMS), safety profiles, skin-nasal-bronchial reactivity, and immunological parameters.A significant reduction was observed in TASS

2016 Journal of investigational allergology & clinical immunology Controlled trial quality: uncertain

329. Fractional exhaled Nitric Oxide monitoring in paediatric asthma management

Fractional exhaled Nitric Oxide monitoring in paediatric asthma management Diagnostic Evidence Co-operative Oxford NIHR Diagnostic Evidence Cooperative Oxford www.oxford.dec.nihr.ac.uk Clinical Questions: Does monitoring of childhood asthma using fractional exhaled nitric oxide (FeNO): a. reduce asthma exacerbations b. reduce steroid prescriptions c. improve asthma-related quality of life Background, Current practice and Advantages over Existing Technology: Current recommendations (...) are that children with asthma should be reviewed 6 monthly at minimum ac- cording to The National Heart, Lung and Blood Institute (NHLBI) guidelines in America (1), or annually ac- cording to The Scottish Intercollegiate Guideline Network (SIGN) (2) and the National Institute for Health and Care Excellence (NICE) (3) in the UK. NICE and SIGN suggest this review should include an assessment of control by monitoring the severity and frequency of exacerbations, inhaler adherence and technique plus a symptom score

2016 Publication 4878904

330. Bronchial thermoplasty for asthma

Bronchial thermoplasty for asthma Final Bronchial Thermoplasty for Asthma: Findings & Decision Page 1 of 3 Health Technology Clinical Committee Findings and Decision Topic: Bronchial Thermoplasty for Asthma Meeting Date: May 20, 2016 Final Adoption: July 8, 2016 Meeting materials and transcript are available on the HTA website: www.hca.wa.gov/hta/meetingmaterials/Forms/ExtMeetingMaterials.aspx Number and Coverage Topic: 20160520A – Bronchial Thermoplasty for Asthma HTCC Coverage Determination (...) : Bronchial thermoplasty for asthma is not a covered benefit. HTCC Reimbursement Determination: Limitations of Coverage: NA Non-Covered Indicators: NA Agency Contact Information: Agency Phone Number Labor and Industries 1-800-547-8367 Public Employees Health Plan 1-800-200-1004 Washington State Medicaid 1-800-562-3022 WA - Health Technology Assessment May 20, 2016 Final Bronchial Thermoplasty for Asthma: Findings & Decision Page 2 of 3 HTCC Coverage Vote and Formal Action: Committee Decision Based

2016 Washington Health Care Authority

331. Pills vs. Puffers: Leukotriene receptor antagonists for childhood asthma

Pills vs. Puffers: Leukotriene receptor antagonists for childhood asthma Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,000 family physicians, family medicine residents and medical students in Alberta. Established over fifty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research (...) . www.acfp.ca January 18, 2016 Pills vs. Puffers: Leukotriene receptor antagonists for childhood asthma Clinical Question: Are leukotriene receptor antagonists (LTRAs) effective in pediatric asthma? Bottom-line: Using leukotriene receptor antagonists instead of inhaled corticosteroids as monotherapy will lead to one more exacerbation in every 21 patients. As add-on to inhaled corticosteroids, leukotriene receptor antagonists are inferior to long acting beta-agonists (LABAs), and show similar outcomes

2016 Tools for Practice

332. Dexamethasone Versus Prednisone for Pediatric Asthma: Will the results take your breath away?

Dexamethasone Versus Prednisone for Pediatric Asthma: Will the results take your breath away? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,400 family physicians, family medicine residents and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary (...) care research. www.acfp.ca May 9, 2016 Dexamethasone Versus Prednisone for Pediatric Asthma: Will the results take your breath away? Clinical Question: Are 1-2 doses of dexamethasone as effective as the standard five day prednisone regimen for treatment of pediatric asthma exacerbations? Bottom-line: Treatment of pediatric asthma exacerbations with short-course dexamethasone (0.6 mg/kg x 1-2 doses) is a safe and effective alternative to traditional five day courses of prednisone. For every ~20

2016 Tools for Practice

334. Adult asthma guidelines

Adult asthma guidelines ADULT ASTHMA GUIDELINES83 NZMJ 18 November 2016, Vol 129 No 1445 ISSN 1175-8716 © NZMA www.nzma.org.nz/journal Asthma and Respiratory Foundation NZ adult asthma guidelines: a quick reference guide Richard Beasley, Robert J Hancox, Matire Harwood, Kyle Perrin, Betty Poot, Janine Pilcher, Jim Reid, Api Talemaitoga, Darmiga Thayabaran ABSTRACT The purpose of the Asthma and Respiratory Foundation NZ Adult Asthma Guidelines is to provide simple, practical and evidence-based (...) recommendations for the diagnosis, assessment and management of asthma in adults (aged 16 and over) in a quick reference format. The intended users are health professionals responsible for delivering asthma care in the community and hospital Emergency Department settings, and those responsible for the training of such health professionals. Abbreviations: ABG Arterial Blood Gas ACT Asthma Control Test ACOS Asthma/COPD overlap syndrome COPD Chronic obstructive pulmonary disease CXR Chest X-Ray DHB District

2016 Asthma and Respiratory Foundation NZ

335. Evaluation and Management of Asthma in the Elderly

2014;60:99–107. 6 Kannan JA, Bernstein DI, Bernstein CK, Ryan PH, Bernstein JA, Villareal MS, Smith AM, Lenz PH, Epstein TG. Signi?cant predictors of poor quality of life in older asthmatics. Ann Allergy Asthma Immunol 2015;115:198–204. 7 Moorman JE, Akinbami LJ, Bailey CM, Zahran HS, King ME, Johnson CA, Liu X. National surveillance of asthma: United States, 2001- 2010. Vital Health Stat 3 2012;35:1–58. 8 Tsai CL, Lee WY, Hanania NA, Camargo CA Jr. Age-related differences in clinical outcomes (...) Evaluation and Management of Asthma in the Elderly AMERICANTHORACICSOCIETY DOCUMENTS AnOf?cialAmericanThoracicSocietyWorkshopReport:Evaluation andManagementofAsthmaintheElderly Gwen S. Skloot, Paula J. Busse, Sidney S. Braman, Elizabeth J. Kovacs, Anne E. Dixon, Carlos A. Vaz Fragoso, Nicola Scichilone, Y. S. Prakash, Christina M. Pabelick, Sameer K. Mathur, Nicola A. Hanania, Wendy C. Moore, PeterG.Gibson,SusanZieman,andBetinaB.Ragless;onbehalfoftheATSadhocCommitteeonAsthmaintheElderly

2016 American Thoracic Society

336. Asthma, Diagnosis and Management of

Asthma, Diagnosis and Management of Asthma, Diagnosis and Management of | ICSI The MN Health Collaborative includes physicians and other representatives from major healthcare organizations working together to address major health topics affecting Minnesota communities today. ICSI has been developing evidence-based clinical practice guidelines to improve patient care since 1993. ICSI helps forward-focused Minnesota health organizations find ways to redefine and redesign systems and the market (...) . Together, we aim to improve care and reduce costs for our patients, families and communities. e Guidelines Asthma, Diagnosis and Management of Revision Date: December 2016 / Eleventh Edition Endorsement Summary The ICSI Diagnosis and Management of Asthma guideline work group endorsed 2016 Global Strategy for Asthma Management and Prevention Report with added qualifications/comments. This report addresses the diagnosis and management of asthma in the pediatric and adult population. The GINA website

2016 Institute for Clinical Systems Improvement

337. Randomised controlled trial: Aerobic exercise training reduces bronchial hyper-responsiveness and serum pro-inflammatory cytokines in patients with asthma

Randomised controlled trial: Aerobic exercise training reduces bronchial hyper-responsiveness and serum pro-inflammatory cytokines in patients with asthma Aerobic exercise training reduces bronchial hyper-responsiveness and serum pro-inflammatory cytokines in patients with asthma | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use (...) in patients with asthma Article Text Therapeutics/Prevention Randomised controlled trial Aerobic exercise training reduces bronchial hyper-responsiveness and serum pro-inflammatory cytokines in patients with asthma Stefano R del Giacco 1 , Vanessa Garcia-Larsen 2 Statistics from Altmetric.com Commentary on: França-Pinto A , Mendes FAR , de Carvalho-Pinto RM , et al . Aerobic training decreases bronchial hyper-responsiveness and systemic inflammation in patients with moderate or severe asthma: a randomised

2016 Evidence-Based Medicine

338. A repeated short educational intervention improves asthma control and quality of life Full Text available with Trip Pro

A repeated short educational intervention improves asthma control and quality of life We assessed the effectiveness of an asthma educational programme based on a repeated short intervention (AEP-RSI) to improve asthma control (symptom control and future risk) and quality of life. A total of 230 adults with mild-to-moderate persistent uncontrolled asthma participated in a 1-year cluster randomised controlled multicentre study. The AEP-RSI was given in four face-to-face sessions at 3-month (...) intervals, and included administration of a written personalised action plan and training on inhaler technique. Centres were randomised to the AEP-RSI (intervention) group or usual clinical practice group. Specialised centres using a standard educational programme were the gold standard group. A significant improvement in the Asthma Control Test score was observed in all three groups (p<0.001), but improvements were higher in the intervention and gold standard groups than in the usual clinical practice

2016 EvidenceUpdates Controlled trial quality: uncertain

339. Helicobacter pyloriinfection and asthma: Is there a direct or an inverse association? A meta-analysis Full Text available with Trip Pro

cases), observational study, performed using biopsy samples (quality: 4/5), an inverse association between H. pylori and pediatric asthma was demonstrated ( P < 0.005). Association between Helicobacter pylori infection and Asthma in paediatric population. Ref. Method for assessing H. pylori infection Association No. of asthmatic/No. of control Age Quality Annagür et al [ ] Serological Seropositivity was similar in acute exacerbations and stable asthmatics 79/36 5-15 3/5 Zevit et al [ ] 13 C-urea (...) not confirmed by two monocentric studies: (4) an Iranian study [ ] , sample size: 196 participants, follow-up: 13 mo, cross-sectional study (quality: 2/5) performed in 98 asthmatic Iranian children, that found a similar H. pylori prevalence in cases and controls; and (5) an European study [ ] , sample size: 3797, prospective (quality: 3/5) performed in 3062 children, was found an association between H. pylori and risk of asthma (OR = 1.75, 95%CI: 1.07-2.87); children infected by CagA- H. pylori strain had

2016 World journal of meta-analysis

340. Mepolizumab (Nucala, GlaxoSmithKline plc.) for the Treatment of Severe Asthma with Eosinophilia: Effectiveness, Value, and Value Based Price Benchmarks

Mepolizumab (Nucala, GlaxoSmithKline plc.) for the Treatment of Severe Asthma with Eosinophilia: Effectiveness, Value, and Value Based Price Benchmarks ©Institute for Clinical and Economic Review, 2016 Mepolizumab (Nucala®, GlaxoSmithKline plc.) for the Treatment of Severe Asthma with Eosinophilia: Effectiveness, Value, and Value- Based Price Benchmarks Final Report March 14, 2016 Institute for Clinical and Economic Review ©Institute for Clinical and Economic Review, 2016 Page i Final Report (...) . Public and Representative Private Insurer Coverage Policies 59 Appendix D. Previous Systematic Reviews and Technology Assessments 63 Appendix E. Ongoing Studies 64 Appendix F. Comparative Clinical Effectiveness Supplemental Information 66 Appendix G. Comparative Value Supplemental Information 70 Appendix H. Conflict of Interest Disclosures 73 ©Institute for Clinical and Economic Review, 2016 Page iv Final Report - Mepolizumab List of Acronyms Used in this Report ACQ Asthma Control Questionnaire ACT

2016 California Technology Assessment Forum